Squarepoint’s Centessa Pharmaceuticals CNTA Stock Holding History

Squarepoint’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,900	Closed	-$229K	–	4564
2025 Q1	$229K	Buy	+15,900	New	+$260K	﹤0.01%	3926

Squarepoint's CNTA Position: Q2 2026 in Review

Squarepoint sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 50,606 shares — an estimated $2.01M sold.

Squarepoint first reported a position in CNTA in Q2 2021 and held it in 8 quarters. The position peaked at $2.05M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Squarepoint reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 50,606 Centessa Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
Squarepoint first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Squarepoint's Centessa Pharmaceuticals position peaked at $2.05M in Q4 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.